Candel Therapeutics, Inc. (CADL)
Nasdaq: CADL · Biological Products, (No Diagnostic Substances) · Needham, MA · filing with the SEC since 2021
Who owns Candel Therapeutics, Inc.
As filed with the SECHolders of 5% or more
5
Fmr LLC holds 15% of COMMON STOCK, as its SCHEDULE 13G/A filed Feb 7, 2025 says.
Directors and officers
17
report now, of 26 people on the record since 2021. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 5 named at left.
Holders of 5% or moreshare of the class, as filed
Fmr LLC
SCHEDULE 13G/A · filed Feb 7, 2025 · COMMON STOCK · 9.3% in Feb 7, 2025
RTW Investments, LP
SCHEDULE 13G · filed May 15, 2026 · Common Stock, $0.01 par value
Paul B Manning
SCHEDULE 13D/A · filed Mar 18, 2026 · Common Stock, $0.01 par value per share
Blackrock, Inc.
SCHEDULE 13G · filed Jul 27, 2026 · Common Stock · 4.2% in Apr 27, 2026
Anders Hove
SCHEDULE 13G · filed Jun 30, 2025 · Common stock, par value $0.0001 per share
Baker Bros. Advisors LP
SCHEDULE 13G/A · filed May 15, 2025 · Common Stock, par value $0.01 per share · reported falling below 5%, from 6.8% in Feb 14, 2025
Northpond Ventures, LP
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock, $0.01 par value per share · reported falling below 5%
CVI Investments, Inc.
SCHEDULE 13G/A · filed Feb 7, 2025 · Common Stock, $0.01 par value per share · reported falling below 5%
What CADL reports owning in othersstakes of 5% or more, and other ties
Candel Therapeutics, Inc. reports no stake in another company in the record.
Insider tradesForm 4
5sales
1purchases
5sales on a scheduled plan
3people selling
$3.6Msold, in dollars
$3.0Mbought, in dollars
Open-market trades on Form 4 from Nov 5, 2025 to Nov 5, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 5, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window4 of 26 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Tak Paul Peter | Chief Executive Officer | 2 | $3.2M | 2 | 0 | $0 |
| Tyagarajan Seshu | Chief Technology Officer | 2 | $200,000 | 2 | 0 | $0 |
| Barone Francesca | Chief Scientific Officer | 1 | $200,000 | 1 | 0 | $0 |
| Manning Paul B | director | 0 | $0 | 0 | 1 | $3.0M |